A Study to Evaluate Serum Testosterone Levels in Patients With Metastatic Castration-Resistant Prostate Cancer (STAAR)
![]() |
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT02737332 |
Recruitment Status :
Completed
First Posted : April 13, 2016
Results First Posted : August 12, 2020
Last Update Posted : November 22, 2021
|
- Study Details
- Tabular View
- Study Results
- Disclaimer
- How to Read a Study Record
Condition or disease | Intervention/treatment | Phase |
---|---|---|
Prostate Cancer | Drug: Zytiga® (Abiraterone Acetate) Drug: SoluMatrix™ (Abiraterone Acetate) | Phase 2 |
Study Type : | Interventional (Clinical Trial) |
Actual Enrollment : | 53 participants |
Allocation: | Randomized |
Intervention Model: | Parallel Assignment |
Masking: | None (Open Label) |
Primary Purpose: | Treatment |
Official Title: | A Randomized, Open-Label, Active-Controlled, Multi-Center Study to Evaluate Serum Testosterone Levels in Patients With Metastatic Castration-Resistant Prostate Cancer: The STAAR STUDY |
Actual Study Start Date : | March 21, 2016 |
Actual Primary Completion Date : | February 27, 2017 |
Actual Study Completion Date : | February 27, 2017 |

Arm | Intervention/treatment |
---|---|
Active Comparator: Zytiga® (Abiraterone Acetate)
1,000 MG (4 x 250 mg qd)
|
Drug: Zytiga® (Abiraterone Acetate)
Zytiga® 1,000 mg (4 x 250 mg qd) tablets plus one 5 mg prednisone tablet to be taken bid, spaced approximately 12 hours apart
Other Name: Zytiga® |
Experimental: SoluMatrix™ (Abiraterone Acetate)
500 mg (4 x 125 mg qd)
|
Drug: SoluMatrix™ (Abiraterone Acetate)
SoluMatrix™ 500 mg (4 x 125 mg qd) tablets plus one 4 mg methylprednisolone tablet bid, spaced approximately 12 hours apart
Other Name: SoluMatrix™ |
- Testosterone Levels [ Time Frame: Average of Day 9 and 10 ]Blood Sample tested for Serum Testosterone Levels
- PSA Levels [ Time Frame: Day 28, Day 56, and Day 84 ]
All patients randomized to one of the two treatment groups, round about level of PSA.
These were assessed only at the said Outcome Measure Time Frame. No additional time points to the said endpoint
- Percent of Subjects With PSA-50 Response [ Time Frame: Day 28, Day 56, and Day 84 ]
Proportion of patients with complete suppression of PSA-50 were reported by treatment and compared for between-group differences.
These were assessed only at the said Outcome Measure Time Frame. No additional time points to the said endpoint.
- Serum Testosterone Levels [ Time Frame: Day 28, Day 56, and Day 84 ]These were assessed only at the said Outcome Measure Time Frame. No additional time points to the said endpoint.
- Steady State Trough Concentration of Arbiraterone [ Time Frame: Day 09, Day 28, Day 56, and Day 84 ]These were assessed only at the said Outcome Measure Time Frame. No additional time points to the said endpoint.
- AUC (0-inf) [ Time Frame: 60 to 30 minutes prior to dosing and over 24 Hours post-dose ]Steady state systemic exposure parameters
- AUC (0-24 hr) [ Time Frame: 60 to 30 minutes prior to dosing and over 24 Hours post-dose ]Blood samples for pre-dose PK profiling were to be collected approximately 45 minutes before dosing, i.e., within 60 to 30 minutes prior to dosing. Post-dose blood samples were to be collected throughout the day at the times (15 mins, 30 mins, 1 hr, 1.5 hr, 2.0 hr 3 hr, 4 hr, 6 hr, 8 hr, 9 hr, 24 hr).
- AUC (0-t) [ Time Frame: 60 to 30 minutes prior to dosing and over 24 Hours post-dose ]Blood samples for pre-dose PK profiling were to be collected approximately 45 minutes before dosing, i.e., within 60 to 30 minutes prior to dosing. Post-dose blood samples were to be collected throughout the day at the times (15 mins, 30 mins, 1 hr, 1.5 hr, 2.0 hr 3 hr, 4 hr, 6 hr, 8 hr, 9 hr, 24 hr).
- Cmax [ Time Frame: 60 to 30 minutes prior to dosing and over 24 Hours post-dose ]Blood samples for pre-dose PK profiling were to be collected approximately 45 minutes before dosing, i.e., within 60 to 30 minutes prior to dosing. Post-dose blood samples were to be collected throughout the day at the times (15 mins, 30 mins, 1 hr, 1.5 hr, 2.0 hr 3 hr, 4 hr, 6 hr, 8 hr, 9 hr, 24 hr).

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study: | 18 Years and older (Adult, Older Adult) |
Sexes Eligible for Study: | Male |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
- Written informed consent obtained prior to any study-related procedure being performed
- Male subjects at least 18 years of age or older at time of consent
- Pathologically confirmed adenocarcinoma of the prostate
- Ongoing therapy with a GnRH agonist or antagonist AND serum testosterone level <50 ng/dL at screening
- Metastatic disease documented by computed tomography (CT)/ magnetic resonance imaging (MRI) or bone scan. Imaging obtained within 42 days prior to the start of study medication will be accepted.
-
Meeting disease progression according to the recommendations of the prostate cancer working group 2 by one of the following criteria:
- Two rises of PSA (taken a minimum of 1 week apart) from a baseline measurement of at least 2 ng/mL,
- Imaging progression (CT/MRI) by RECIST criteria
- Nuclear scan progression by new lesion.
- Discontinuation of flutamide or nilutamide, and other anti-androgens at least 4 weeks prior to the start of study medication; discontinuation of bicalutamide at least 6 weeks prior to start of study medication.
- Discontinuation of Radiotherapy > 4 weeks prior to start of study medication.
- ECOG performance status of 0-1 at screening
-
Screening blood counts of the following:
- Absolute neutrophil count > 1500/µL
- Platelets > 100,000/µL
- Hemoglobin > 9 g/dL
-
Screening chemistry values of the following:
- ALT and AST < 2.5 x ULN
- Total bilirubin < 1.5 x ULN
- Creatinine< 1.5 x ULN
- Albumin > 3.0 g/dL
- Potassium > 3.5 mmol/L
- Life expectancy of at least 6 months at screening
- Subject is willing and able to comply with all protocol requirements assessments
- Agrees to protocol-defined use of effective contraception.
Exclusion Criteria:
- History of impaired pituitary or adrenal gland function
- Prior therapy with abiraterone acetate, orteronel, ketoconazole or any other CYP17 inhibitor
- Prior therapy with enzalutamide
- Prior use of experimental androgen receptor antagonist
- Previous exposure to Ra-223:Xofigo
- Previous chemotherapy
- Initiation of bisphosphonate or denosumab therapy within 30 days prior to the start of study medication. Patients who are on a stable dose of these medications for at least 30 days at the time of starting study drug are eligible.
- Therapy with estrogen within 30 days prior to the start of study medication
- Use of systemic glucocorticoids equivalent to > 10 mg of prednisone daily; patients who have discontinued or have reduced dose to < 10 mg prednisone within 14 days prior to the start of study medication will be eligible
- Prior use of any herbal products that may decrease PSA levels (eg., saw palmetto) within 30 days of start of study medication
- Known metastases to the brain or CNS involvement
- History of other malignancy within the previous 2 years
- Major surgery within 30 days prior to the start of study medication
- Blood transfusion within 30 days of screening
- Serious, persistent infection within 14 days of the start of study medication
- Persistent pain that requires the use of a narcotic analgesic
- Known gastrointestinal disease or condition that may impair absorption
- Treatment with any investigational drug within 4 weeks prior to Day -1 of the study.
- Known history of human immunodeficiency virus (HIV) or seropositive test for hepatitis C virus or hepatitis B virus
- Have poorly controlled diabetes.
- Uncontrolled hypertension
- History of New York Heart Association (NYHA) class III or IV heart failure
- Serious concurrent illness, including psychiatric illness, that would interfere with study participation
- Inability to swallow tablets whole
- Known hypersensitivity to any excipients in study medications
- Moderate to severe hepatic impairment (Child-Pugh Classes B and C)

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02737332

Study Director: | Paul Nemeth, PhD |
Documents provided by Sun Pharmaceutical Industries Limited:
Responsible Party: | Sun Pharmaceutical Industries Limited |
ClinicalTrials.gov Identifier: | NCT02737332 |
Other Study ID Numbers: |
CHL-AA-201 |
First Posted: | April 13, 2016 Key Record Dates |
Results First Posted: | August 12, 2020 |
Last Update Posted: | November 22, 2021 |
Last Verified: | November 2021 |
Individual Participant Data (IPD) Sharing Statement: | |
Plan to Share IPD: | No |
Prostatic Neoplasms Genital Neoplasms, Male Urogenital Neoplasms Neoplasms by Site Neoplasms Prostatic Diseases Abiraterone Acetate Antineoplastic Agents |
Steroid Synthesis Inhibitors Enzyme Inhibitors Molecular Mechanisms of Pharmacological Action Hormone Antagonists Hormones, Hormone Substitutes, and Hormone Antagonists Physiological Effects of Drugs Cytochrome P-450 Enzyme Inhibitors |